Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
SWOG Cancer Research Network
OHSU Knight Cancer Institute
Bristol-Myers Squibb
Milton S. Hershey Medical Center
Institut Bergonié
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
Teva Branded Pharmaceutical Products R&D, Inc.
Bristol-Myers Squibb
Novartis
Bristol-Myers Squibb